Latest news with #Phibro
Business Wire
a day ago
- Business
- Business Wire
Phibro Animal Health Corporation to Host Webcast and Conference Call on Fourth Quarter and Fiscal Year 2025 Results
TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) expects to announce its fourth quarter and fiscal year 2025 financial results on Wednesday, August 27, 2025, after the market closes. Phibro management will host a conference call and webcast on Thursday, August 28, 2025, at 9:00 AM Eastern Time. Interested parties are invited to listen to the conference call and view the presentation slides by visiting The discussion will also be available by dialing +1 (888) 330-2022 in the U.S. and Canada, or +1 (365) 977-0051 for international callers. Provide the conference ID 3927884. A replay of the webcast will be available approximately two hours after the conclusion of the live event. To access the webcast recording, visit About Phibro Animal Health Corporation Phibro Animal Health Corporation is a leading global diversified animal health and mineral nutrition company. We strive to be a trusted partner with livestock producers, farmers, veterinarians, and consumers who raise or care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals. For further information, please visit Our filings with the Securities and Exchange Commission are available online at or on request from the company.
Yahoo
a day ago
- Business
- Yahoo
Phibro Animal Health Corporation (PAHC) Hits Fresh High: Is There Still Room to Run?
A strong stock as of late has been Phibro Animal Health (PAHC). Shares have been marching higher, with the stock up 9% over the past month. The stock hit a new 52-week high of $32.08 in the previous session. Phibro has gained 51.7% since the start of the year compared to the -2.9% gain for the Zacks Medical sector and the 6.1% return for the Zacks Medical - Products industry. What's Driving the Outperformance? The stock has a great record of positive earnings surprises, having beaten the Zacks Consensus Estimate in each of the last four quarters. In its last earnings report on May 7, 2025, Phibro reported EPS of $0.63 versus consensus estimate of $0.52. For the current fiscal year, Phibro is expected to post earnings of $2.3 per share on $1.28 in revenues. Meanwhile, for the next fiscal year, the company is expected to earn $2.54 per share on $1.41 in revenues. This represents a year-over-year change of 12.99% and 10.14%, respectively. Valuation Metrics Though Phibro has recently hit a 52-week high, what is next for Phibro? A key aspect of this question is taking a look at valuation metrics in order to determine if the company has run ahead of itself. On this front, we can look at the Zacks Style Scores, as these give investors a variety of ways to comb through stocks (beyond looking at the Zacks Rank of a security). The individual style scores for Value, Growth, Momentum and the combined VGM Score run from A through F. The idea behind the style scores is to help investors pick the most appropriate Zacks Rank stocks based on their individual investment style. Phibro has a Value Score of A. The stock's Growth and Momentum Scores are A and D, respectively, giving the company a VGM Score of A. In terms of its value breakdown, the stock currently trades at 13.8X current fiscal year EPS estimates, which is not in-line with the peer industry average of 18.5X. On a trailing cash flow basis, the stock currently trades at 15.1X versus its peer group's average of 11.2X. Additionally, the stock has a PEG ratio of 0.53. This is good enough to put the company in the top echelon of all stocks we cover from a value perspective, making Phibro an interesting choice for value investors. Zacks Rank We also need to look at the Zacks Rank for the stock, as this supersedes any trend on the style score front. Fortunately, Phibro currently has a Zacks Rank of #2 (Buy) thanks to rising earnings estimates. Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if Phibro meets the list of requirements. Thus, it seems as though Phibro shares could still be poised for more gains ahead. How Does PAHC Stack Up to the Competition? Shares of PAHC have been soaring, and the company still appears to be a decent choice, but what about the rest of the industry? One industry peer that looks good is Brainsway Ltd. Sponsored ADR (BWAY). BWAY has a Zacks Rank of #2 (Buy) and a Value Score of C, a Growth Score of A, and a Momentum Score of A. Earnings were strong last quarter. Brainsway Ltd. Sponsored ADR beat our consensus estimate by 42.86%, and for the current fiscal year, BWAY is expected to post earnings of $0.34 per share on revenue of $50.88 million. Shares of Brainsway Ltd. Sponsored ADR have gained 19.6% over the past month, and currently trade at a forward P/E of 42.56X and a P/CF of 58.03X. The Medical - Products industry is in the top 40% of all the industries we have in our universe, so it looks like there are some nice tailwinds for PAHC and BWAY, even beyond their own solid fundamental situation. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Phibro Animal Health Corporation (PAHC) : Free Stock Analysis Report Brainsway Ltd. Sponsored ADR (BWAY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
03-07-2025
- Business
- Yahoo
Phibro Animal Health Corporation (PAHC) Hit a 52 Week High, Can the Run Continue?
A strong stock as of late has been Phibro Animal Health (PAHC). Shares have been marching higher, with the stock up 9.5% over the past month. The stock hit a new 52-week high of $26.77 in the previous session. Phibro has gained 26.8% since the start of the year compared to the -2.7% gain for the Zacks Medical sector and the 7.6% return for the Zacks Medical - Products industry. The stock has an impressive record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any of the last four quarters. In its last earnings report on May 7, 2025, Phibro reported EPS of $0.63 versus consensus estimate of $0.52 while it missed the consensus revenue estimate by 0.78%. For the current fiscal year, Phibro is expected to post earnings of $2.29 per share on $1.28 in revenues. Meanwhile, for the next fiscal year, the company is expected to earn $2.52 per share on $1.41 in revenues. This represents a year-over-year change of 12.5% and 10.35%, respectively. Phibro may be at a 52-week high right now, but what might the future hold for the stock? A key aspect of this question is taking a look at valuation metrics in order to determine if the company is due for a pullback from this level. On this front, we can look at the Zacks Style Scores, as these give investors a variety of ways to comb through stocks (beyond looking at the Zacks Rank of a security). These styles are represented by grades running from A to F in the categories of Value, Growth, and Momentum, while there is a combined VGM Score as well. The idea behind the style scores is to help investors pick the most appropriate Zacks Rank stocks based on their individual investment style. Phibro has a Value Score of A. The stock's Growth and Momentum Scores are A and D, respectively, giving the company a VGM Score of A. In terms of its value breakdown, the stock currently trades at 11.6X current fiscal year EPS estimates, which is not in-line with the peer industry average of 19.5X. On a trailing cash flow basis, the stock currently trades at 12.6X versus its peer group's average of 10.9X. Additionally, the stock has a PEG ratio of 0.45. This is good enough to put the company in the top echelon of all stocks we cover from a value perspective, making Phibro an interesting choice for value investors. We also need to look at the Zacks Rank for the stock, as this supersedes any trend on the style score front. Fortunately, Phibro currently has a Zacks Rank of #1 (Strong Buy) thanks to favorable earnings estimate revisions from covering analysts. Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if Phibro passes the test. Thus, it seems as though Phibro shares could have a bit more room to run in the near term. Shares of PAHC have been soaring, and the company still appears to be a decent choice, but what about the rest of the industry? One industry peer that looks good is Perrigo Company plc (PRGO). PRGO has a Zacks Rank of #2 (Buy) and a Value Score of A, a Growth Score of D, and a Momentum Score of D. Earnings were strong last quarter. Perrigo Company plc beat our consensus estimate by 7.14%, and for the current fiscal year, PRGO is expected to post earnings of $3.03 per share on revenue of $4.44 billion. Shares of Perrigo Company plc have gained 3.4% over the past month, and currently trade at a forward P/E of 9.06X and a P/CF of 5.43X. The Medical - Products industry may rank in the bottom 61% of all the industries we have in our universe, but there still looks like there are some nice tailwinds for PAHC and PRGO, even beyond their own solid fundamental situation. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Phibro Animal Health Corporation (PAHC) : Free Stock Analysis Report Perrigo Company plc (PRGO) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
06-06-2025
- Business
- Yahoo
Phibro (PAHC) Up 7.4% Since Last Earnings Report: Can It Continue?
A month has gone by since the last earnings report for Phibro Animal Health (PAHC). Shares have added about 7.4% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Phibro due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. It turns out, fresh estimates have trended downward during the past month. Currently, Phibro has a great Growth Score of A, a grade with the same score on the momentum front. Following the exact same course, the stock was allocated a grade of A on the value side, putting it in the top 20% for this investment strategy. Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in. Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Phibro has a Zacks Rank #1 (Strong Buy). We expect an above average return from the stock in the next few months. Phibro belongs to the Zacks Medical - Products industry. Another stock from the same industry, ResMed (RMD), has gained 2.7% over the past month. More than a month has passed since the company reported results for the quarter ended March 2025. ResMed reported revenues of $1.29 billion in the last reported quarter, representing a year-over-year change of +7.9%. EPS of $2.37 for the same period compares with $2.13 a year ago. ResMed is expected to post earnings of $2.47 per share for the current quarter, representing a year-over-year change of +18.8%. Over the last 30 days, the Zacks Consensus Estimate has changed -0.2%. ResMed has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of B. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Phibro Animal Health Corporation (PAHC) : Free Stock Analysis Report ResMed Inc. (RMD) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
23-04-2025
- Business
- Business Wire
Phibro Animal Health Corporation to Host Webcast and Conference Call on Third Quarter Results
TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) expects to announce its third quarter financial results on Wednesday, May 7, 2025, after the market closes. Phibro management will host a conference call and webcast on Thursday, May 8, 2025, at 9:00 AM Eastern Time. Interested parties are invited to listen to the conference call and view the presentation slides by visiting The discussion will also be available by dialing +1 (888) 330-2022 in the U.S. and Canada, or +1 (365) 977-0051 for international callers. Provide the conference ID 3927884. A replay of the webcast will be available approximately two hours after the conclusion of the live event. To access the webcast recording, visit About Phibro Animal Health Corporation Phibro Animal Health Corporation is a leading global diversified animal health and mineral nutrition company. We strive to be a trusted partner with livestock producers, farmers, veterinarians, and consumers who raise or care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals. For further information, please visit Our filings with the Securities and Exchange Commission are available online at or on request from the company.
